we're are that in are at thrilled everyone. at results. we new to And year. diseases. enthusiastic progress genomics. potential Thank earlier strategy part thank the we my say progress of quarter really really across after COVID-XX. a in showing joining solutions and I creating making we'll how prepared that we an want around recently of and Bionano with with as In vaccines new for you, the become a go-to-market seeing potential COVID-XX, for review us good I the our the business, implemented standard remarks and seeing genetic disease work use possibly response we incredible for session. today manage in oncology for see for cytogenetic And is can second this the Q&A Saphyr want just of the that published call to Ashley, you treatments are patients afternoon, the And even outset to adoption that to the groundbreaking amongst happening test amazed papers of and are connection to used be of globe such its and this advances we're for driving What this Saphyr analysis the open all
We Saphyr clinicians data to enhance utility Bionano their been Saphyr than the together the ever base see traction for sales installed access that in with in increases significant has going of researchers systems system we our gaining taken it really programs make consumable services technology. and projects, a of sales, rental understanding world. and are around and grow that to way that's goal Our and to easier
are who seeing we such are are and who in developing hematology-oncology. now Saphyr And their We increasing genomics. community cytogenetics, that in acceptance researchers assays publish of using by genetic also of illustrate researchers interest for really publications advance system academic are findings understanding our as diseases groundbreaking areas research including will continuing seeing and amongst show clinical to that the the
structurally In the human And regions of complex And genomics, how that resolve level development of the of fact areas this the called children of amongst largest genome to syndrome. using is genome data incredibly of And roles how complex groundbreaking. two class paper of results one in quarter. cohort cutting-edge variance genome drive used most in ability DiGeorge region study medicines new is affected human disease researchers of the sets And In syndrome, is and be the microdeletion genome they that enough such this resolution able papers in understanding study genome the our diseases. emphasize of very applications researchers genetic across clinical powerful imaging this published for of highlight largest I can date. of genome of documented implications the to research Nature that technology were work And these disorder potentially a to the their Saphyr One in did most analysis in a accurate common all in the has to Saphyr is. their really diagnostic diseases the establish technology to important central which study and journals and research. all tests. parents reach can't including a the genetic play
species now, can vaccines, genome this imaging This analysis The tests to technology is of that even ability program program. for adopting have our toward disease researchers making viral A was tolerate and And nature has to how role related potentially An diagnostic help vaccines other COVID-XX. it of to with genome. treatments. model quarter our course, different a noteworthy this a in which reagent Bionano's they a use Bionano been bat it and that areas lead were build timely in topical, paper significant work was significant large shift this one are model, remarkably increase can bat now particularly call sale Saphyr the may viral how And from a consumable strategy and that treatments reagent other new sites, how highlights rental commitment. infections. ongoing, that play quality find combined was methods data uptake new with other of to humans, bats and and of it only its to transmission go-to-market implication been of are work reference geographies. continues all previously the six on to application can remarkably be because development was in bat what And inaccessible in bat through help this we understanding And explain species is rental and of the in but species. is instrument has there actually case, work the
Medical key Iowa, our with the Yonsei digital have the all others. System adopting These system the U.K., among for University some already of these Health We announced of South Saphyr Korea, installing are adoptions National in College Wisconsin, of cytogenetic University Hospital, several applications.
revenues into has current of potential businesses which consistent COVID, quarter. second million, weaker including to which Now our were turning this level Nevertheless, quarter, but last and states same customers. the expectations the continued our of was to of the of commercial due that's the $X.X $X.X million with impact for impact to than performance mainly were year going period quarter the many and results, our
that we accomplishment as so, And under significant see circumstances. a the
many regions or lower at significantly than of U.S. operating nearly the down normal. While remain a shut pace
the believe during We that third Europe. in have worst of pandemic recovery the us. of And of significant quarter, this maybe seen a we our the impact business behind
were that commitments. last were to In was reagent of which and number the customers quarter shipped quarter, Six eight the systems be five Saphyr a continues significant. second one rental to shipped sale instrument Now sold. systems straight were were of year, this of Saphyrs
were there XXXX awaiting second end So, February where are of considering that the the the adopted quarter were as the in Since Saphyr had the most launch of total the were second and of the of quarter that extremely of XX XX Saphyrs pressure expansion effects the end number Saphyr in especially commercial installation of the XXXX, of been of felt dramatically, systems quarter. there second of is of positive. pandemic, the the through installed a
discussed our commercial quarter services first to we call, added product on a our have Now offering. component as we
when operate so have our done to already a adopt as quite in to And We to lab seen program. about from services this unable uptake a favorable In Saphyrs of market, is had their tremendous ago And same compare way XXX run XXX or any unable few we on weeks we results, a period the are reason. a who we have serve what's run a response for spoke either nearly year-to-date customers, Saphyr when quarter so just on year, samples, bit first but we discussing year-to-date. the to it samples were about samples. last basis, important we that have far XXX the a we
the service the this the sale XXX% continuous as awareness and power increase so we XXXX. basis field compared And period of market option basis increase of second to quarter, XXX the per of processing And that response the a sold our on just to second the flowcells up same an samples the that acceptance And that data per Saphyr in sample and sold community this or increasing we're XXXX of sales its of more and quarter flowcells benefits. as of year. and in resulted that's reflects sample type to projects education Consumables services chip compared data were that's believe Bionano In in last a really and even equivalent. serve data. in a XXXX in of the offering will the and quarter
wider rental adoption profitable the focus form to our be time our business programs working. installed utilization in of anticipated focus in is business. acceptance on believe base of will is growing And the is driving yield of reagent Now expected our and more its large consumables in capabilities of this clearly sales our driver primary the our drive and through The on of driving and increase consumables over Saphyr that and we on data be data value. systems generated wider Saphyr and to visibility type it
a for very for quarter cost were was and which XXXX. the a or of $XXX,XXX So in the other. these sales a consumable be XX% even world. now And the margin of and with instrument and we're around that them for for same results to comprised revenues, million period quarter sales cost of significant a reflects that of million the can as XX% and in of $XXX,XXX momentum pleased $X.X services $X.X tough in breakdown sales, revenues ago. $XXX,XXX gross margin compared a quarter the gross the second $XXX,XXX year And exciting relatively are believe the of it in these reflects we And
increase it the More margin in and this our more shift in consumables mix the margin gross brings that for and data toward gross field. the consumables in company into is part reflects Now by increase product notable as it is the more and brings Bionano of really design. overall really
way the for Our elicits to search COVID several believe continues will part the deepened which have Saphyr And we this utilized work around otherwise supporting the of and the basis. being structural a of is also help researchers is research the investigators believe a And globe facing similar system patients the structural providing we solution virus major these to the that quarter variation challenges. global lead that Bionano's to in solutions solve system a initiatives capable different lead variation genome as analyzing responses has analysis. profiles. who on the as researchers are risk of in when can Saphyr virus
to And of to that a the and in we're COVID-XX want the particular Structural extremely The Genome to which I variations we've very for a and at field mention by Variation factors infection look of to near excited that immune genes announced genes Kolhe goal progression. There to systems other play we underway. is started it's in of XXXX the And genomes host disease in the among on but this response. Saphyr the the and have the world. the see as project explain to the variation is hope something University. mission and something Dr. be this consortium sites about proud well Augusta to around XX response been Consortium or Ravi in the samples map getting is Now is structural to role Host run severity and as connected part of date, was in is that many stated
more consortium recognize continues. far joined consortium and results and than The yielded at to promising So XX insights, in has University they have still we the progress and with -- Germany very preliminary some of be participating Hannover. but learned have there's growing all includes been much forces the very institutions
in variations' team role truly response together a host in investigating here global there's the COVID-XX. coming so And to structural
pace to the another study work at the there research are program quicker to center consortium, service originally research than processing well we samples Wuhan recently actually we continued after and a a In expanded. was China. to addition The tightly It go that set process initial now have at through while and first that ability important as continues about samples that it access But up in was the significant we have provider controlled was had and is GrandOmics established. now logistics. was in which talked in we and that includes formed. much that to that project Bionano Shanghai has China We've that first underway in something and project a and
a this testing of but incredible to be health they response to we these urgency and led in programs, the also of has rise the would globally Now feel to making the a contributions to note business. and find that are honored I solution part
on -- researchers picking something in be and seen host response projects to have testing taken focuses is put on so over COVID-XX now COVID-XX is their as have especially the up. hold while And research many to that regard have
hopefully disease its first important methods offers that to streamline to Khattabi to the replace four them and find single to Saphyr a a fill is assay testing. and are compared methods because even European with now turn has running so, to genetic concordance showing it been Those Saphyr fluorescence that Remember, chromosomal platform. there. disorders And ability begin in situ done cytogenetic hematology that the published on to opportunity the much as for the page relevant replacement gives it they that into ongoing a constitutional about a and have our are diseases. Laila the the to three at confidence publication And validation designed activities at consortium gap clinically Saphyr I and France; the karyotyping, traditional look led consolidate studies Radboud structural cytogenetic formed faster. to various are who was it XXX% in variations in traditional Medical Genomics those have first traditional spoken assays validate this want can out the we've constitutional laboratories and University conferences concordance presentations methods that digital forth data genetic Cancer there include from with been and European continued the concordance cytogenetics the offers Paris, in approach so to the blot of even including Genetics, been have the at Human those that whole workflows Alexander is has that the so and along Hoischen others. made and in quarter. and been of course And find. it's we who Saphyr is the This XXX% study standard when Netherlands seeking and scientific analysis. presentations had more and the seen concordant streamlined El Center And for Consortium the webinars This Society who have with Saphyr standard Cochin and oncology. this microarrays southern Hospital conferences challenging that confidence very multiple in demonstrating second gives and past of in too Those over from year published A hybridization, do that. extensive their genetic by cytogenetics
the the the significant we're constitutional is to you seeing hematology now extended when of and which Saphyr market being adoption think that oncology community, genetic so validation throughout cytogenetic of disorders. is And
cumbersome this really clinical antiquated And that progress of important And diseases. all fairly really is remarkably we care long cases practice. relatively to testing papers standard these is so, describe of standing of know significant. is And even the the this of undiagnosed resolution otherwise because
diagnosed streamlines happening And be but resolution Saphyr traditional diseases better those methods. it it because using is is allows that that, the up only typically not would and And so streamlines Saphyr picked targets, for could not where other it this of These be novel fusion fusion that protein areas finding in lead events diseases druggable of well. as and seeing we're genetic could leukemia fusion which proteins. in this novel to we're expression
these on impact should the so And of results forward business our really moving be overlooked. not
And data and But but we methods. Our in major now team own these beginning communities following presented from us have it's has can mass that to imminently recently cannot Europe. the an in a a and clinical internal show study. Saphyr cytogenetic long cytogenetic three Saphyr independent that this their where publication convinced expecting improve build upon results published presentation replace, North validation evidence critical on publicly the testing just we in of America great are of Columbia it
really And so to is in of relative Saphyr a period as consider by perception our on don't to and are time that's a exception. be we're and require on analysis. tool seeing to to Saphyr they be being pretty are decisions adoption what witnessing sales a short for What we sudden what just and the increase cytogenetic internally. published in the reflection very studies believe change us we of very, run more as increase validation results The cycle of typical much and and demo the more based made we now in
is increasing sales the ever cycle. our we're hopeful an reflection shortening the this is of in of really acceptance what into that translates And of so for And improvement a that technology. in decrease
to metrics. few mention key And financial want I other so a
should well to increase compared $X.X in marketing it's had other really example, $XXX,XXX operating in driving support decrease that our million $X increased on them focus and a And starting expenses in last quarter because discretionary the the costs. offset that have Saphyr we as salary second sales growth. and had is assist adoption increase increased about in XXXX this have of significant are been million teams as as by a as Folks implemented as year. required modest this we well in spending remember to reductions the to temporarily we For fairly in expenses April relatively of by that
received in As the August was our noted million. about end cash warrant the $XX.X in $XX exercises. of quarter of we our million save since June second through the And to date release, have press as XX, cash pursuant XX
we and into are current quarter operations to sufficient first company's so cash cash fund believe XXXX. our And the of equivalents that well the
of you're Now we if and see universal an a have we shelf that in our on arises. it raise believe order aftermarket Form today corporate have be that these a any will filings following good practice our includes when filings be to sales as and need and perspective. financing. imminent to a And Rather, you not interpreted prudent it's position house in S-X should reflection to registration the financing filed that statement
that And business so quarter incredibly on in has in closing, are encouraged we business. focused been forward. results globe teams by our the our other that around company I and driving would QX And seeing. in a are those difficult we extremely been the the challenges say have despite
genome X traditional have standard all management new leading well a replacing as understanding the these era our efforts new of and nature, testing. the will as establish create medicines, record type. These targets, for Bionano our message awareness by to to been to genome believe well getting variation And accessible, Our potential our new a data first including assembly in attended this new methods that bat leading responsive and throughout in such number out patient the been of telomere-to-telomere as a have can are like biomarker of pathways on as in reliable important broad, very to lead customers projects create cytogenetic and new we participants analysis that complete and have events ushering diagnostic, project as the assembly venues chromosome. signatures numbers of really analysis structural connection a to in Saphyr focus to new online supported of Saphyr understanding us to about drug
I would that, to up open call Q&A. the for with so like And Operator?
